The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach

Ann Oncol. 1993 Dec;4(10):839-46. doi: 10.1093/oxfordjournals.annonc.a058390.

Abstract

Background: Primary non-Hodgkin's lymphoma (NHL) of the stomach is a rare disease; diagnosis may be difficult and the method of treatment is at debate, especially the role of surgery. We therefore evaluated clinical findings, in particular endoscopic diagnosis and long-term results of various treatment strategies, especially the effect of the stomach-saving procedure with radiotherapy alone, in patients with stage I and II NHL of the stomach over a 20 year period (1970-91).

Patients and methods: A series of 119 consecutive patients (71m + 48f, median age 62 years) were studied: 80 patients in stage I and 39 in stage II. Treatment schedules were: group A: standard radiotherapy alone, after clinical staging (n = 46); group B: gastric resection followed by standard radiotherapy (n = 28); group C: various combinations of resection, radiotherapy plus or minus chemotherapy (n = 45). Since 1978 surgery was no longer advocated: our resection rate dropped from 83% to 38%.

Results: Symptoms and signs were non-specific: epigastric pain (81%), nausea (33%), vomiting (24%) and weight loss (66%). Haemorrhage or perforation at presentation were unusual, in 14 (12%) and 5 (4%) cases, respectively. At endoscopy 3 main patterns were recognized: ulceration (34%); diffuse infiltration (18%) and a polypoid mass (37%). Endoscopic biopsies were diagnostic in 92%, including 11% after repeated endoscopy. Treatment results were excellent for stage I: local control in 93%, 5-year survival 70%; in stage II the results were less favorable: 57% and 37%, respectively. Recurrences were only seen in 17 cases, among which 10 cases were extra-abdominal. According to treatment schedule, results were similar in group A (n = 46), with radiotherapy alone, and group B (n = 28), with resection plus radiotherapy, leading to a 5-year overall survival of 71% and 82%, respectively (no significant difference). Severe complications of treatment were infrequent: one perforation, another with a fatal haemorrhage in group A. In group C (n = 45) various individualized schemes were applied, usually palliative either due to large tumour extent or patients of old age and poor condition, leading to a 5-year survival of only 31%.

Conclusions: Clear patterns were recognized at endoscopy, and diagnosis on endoscopic biopsies was possible in the vast majority (92%); in clinical stage I radiotherapy alone is effective, safe and well tolerated.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Female
  • Gastroscopy*
  • Humans
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / therapy*
  • Survival Rate
  • Treatment Outcome